{"id":"W2758552192","doi":"10.1016/s1470-2045(17)30566-1","title":"Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":343,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Amgen","keywords":"Medicine; Capecitabine; Epirubicin; Internal medicine; Placebo; Clinical endpoint; Gastroenterology; Phases of clinical research; Cancer; Chemotherapy; Performance status; Oncology; Surgery; Clinical trial; Pathology; Breast cancer; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001655918,0.00221369,0.003676388,0.0003898416,0.000371993,0.001082689,0.001179577,0.001780082,0.004881707],"category_scores_gemma":[0.001469303,0.0008143566,0.002360294,0.0004347998,0.001100586,0.001235068,0.0003913088,0.003863341,0.001170086],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008636621,"about_ca_system_score_gemma":0.0009138197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001149407,"about_ca_topic_score_gemma":0.003032968,"domain_scores_codex":[0.9995327,0.0002231636,0.00002696786,0.00009889489,0.00002869099,0.00008967453],"domain_scores_gemma":[0.9994901,0.000133985,0.0001122411,0.00004491969,0.00002986216,0.0001888196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9748161,0.002913759,0.0002964624,0.001119527,0.00105945,0.00004502856,0.00005449381,0.0003919299,0.00292313,0.000093629,0.0009718969,0.01531464],"study_design_scores_gemma":[0.9591153,0.03858305,0.0008092553,0.00003065261,0.0004132781,0.00003473727,0.00001318277,0.0002506892,0.0002587236,0.00007410463,0.0004040953,0.00001299635],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9786175,0.01287229,0.0006844792,0.000880141,0.0009346341,0.002748114,0.0009457788,0.000247025,0.002070008],"genre_scores_gemma":[0.9815186,0.006642965,0.001413998,0.001234872,0.0005183949,0.002871351,0.001288051,0.00004430924,0.004467517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004881707,"threshold_uncertainty_score":0.01633096,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09008277766277609,"score_gpt":0.4101330386963679,"score_spread":0.3200502610335918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}